AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 16 - (NewsRx.com & NewsRx.net) -- CD4+CD25+ suppressor lymphocytes may modify the T-cell response of melanoma patients' T-cell response undergoing tumor antigen immunization, according to a study by U.S. National Institutes of Health scientists.
"Murine studies have suggested that a population of CD4+ T cells expressing the alpha chain of the interleukin (IL)-2 receptor (CD25+) are phenotypically anergic in response to T-cell receptor stimulation and can suppress the function of CD4+ and CD8+ T cells. Recent studies of peripheral lymphocytes from healthy human volunteers have identified a similar population, although little is known about the presence and activity of these cells in patients with cancer and their possible impact on anticancer immunization strategies," wrote L.R. Javia and colleagues.
In this study, the researchers worked with "patients with metastatic melanoma undergoing immunizations with known melanoma antigens."
"CD4+CD25+, CD4+CD25-, and a 1:1 ratio of these isolated T cells were stimulated with soluble anti-CD3 antibody in the presence of irradiated T-cell-depleted PBMCs, and proliferation was assessed by measuring [H-3]thymidine incorporation," Javia and team explained.
They found that "in 13 patients, isolated CD4+CD25+ T cells proliferated 68% (5.8%) less than separately cultured CD4'CD25- T cells. Moreover, CD4+CD25+ T cells suppressed the proliferation of an equal number of cocultured CD4+CD25+ T cells in ...